Tagmaster’s Q3 report is characterized by a flat topline but strong margins and cash flow.
The FDA has approved Lucamzi, Xbrane’s Lucentis biosimilar, two days ahead of the 29 October BsUFA d...
Redeye provides its initial take on Relais' Q3 2026 report, which showed net sales 4% below our esti...
* Q3 reported EBITDA NOK 18m vs ABGSCe NOK 10m * Sainsbury's still slow, but US and Spain wins build...
Redeye comments on GiG Software’s Q3-results where revenue was slightly above our forecast while adj...
Relais Q3 adjusted EBITA of EUR 11.5m was up 5% y/y and came 5% above Modular Finance consensus of E...
ProTrans-Young missed its primary endpoint, and the preliminary two-year data in the older cohort di...
Lassila & Tikanoja's report was close to our expectations and somewhat above FactSet consensus.
Although Inderes’s Q3 EBITA was slightly ahead of our estimate and we keep our estimates largely unc...
Redeye previews Oncopeptides’ Q3 report, due on 5 November.
* Accretive AM sales +26% y-o-y... * ...while OEM delivery is pushed out * 23/17x EBIT '26e-'27e, ~2...
Redeye updates its estimates after AddLife's Q3 2026 report.
* Q3e: 5% organic growth and 23% EBITA growth y-o-y * Acquisition and AI deal behind 3-4% higher EBI...
Redeye shares its preview of Camurus’ Q3 2026 results, due on 5 November.
* We expect soft sales momentum for Q3e * Negative earnings revisions on lower sales * Q3'26 results...
Marginalåterhämtningen i Entreprenad fortsätter Lönsamheten inom Entreprenad förbättrades under det...
* Sales of SEK 357m, organic growth of 0.5% * Adj. EBITA of SEK 30m, and a margin of 8.
VNV’s Q3 NAV per share landed at SEK 34, -2% q/q. The reported NAV is at USD 439m, -5% q/q.
* Better organic growth (+5% vs. ABGSCe +1%) * AM guide raised to 20-25% (5-15%), OEM narrowed to 45...
Redeye provides an initial take following Neem's Hill's Q3 2026 report.